Drapeau Anne S 4

What Happened

• Anne S. Drapeau, a director of Vaxcyte, was granted awards on 2026-06-15 totaling 13,654 shares: 2,265 restricted stock units (RSUs) and an 11,389-share derivative award. Both awards show an acquisition price of $0.00 (no cash paid) in the Form 4 filing.
• These awards are typical director compensation rather than open-market purchases or sales; they do not represent an immediate sale of shares.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (timely).
• Price: $0.00 for both grants; reported value = $0.
• Total shares awarded: 2,265 RSUs + 11,389 derivative = 13,654 shares.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnotes:
  • F1: The 2,265 RSUs each convert to one share and vest on the earlier of June 15, 2027 or the day before the next annual meeting, subject to acceleration and continuous service.
  • F2: The 11,389-share derivative award vests monthly and fully vests on the earlier of June 15, 2027 or the day before the next annual meeting, subject to acceleration and continuous service.
• No indication of a 10b5-1 plan, tax-withholding sale, or sale of shares immediately following vesting in this filing.

Context

• RSUs and derivative awards are compensation-based grants that vest over time; they are not immediate cash purchases or sales. They are commonly used to align director incentives with shareholder value.
• Because no shares were sold and no cash was paid, this filing reflects a grant of future economic interest rather than an active market bet.